Starpharma Holdings (PQ6) Stock Overview
A biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
PQ6 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Starpharma Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.038 |
| 52 Week High | AU$0.066 |
| 52 Week Low | AU$0.035 |
| Beta | 0.42 |
| 1 Month Change | -1.28% |
| 3 Month Change | -30.00% |
| 1 Year Change | -30.00% |
| 3 Year Change | -92.34% |
| 5 Year Change | -93.94% |
| Change since IPO | -92.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| PQ6 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 6.9% | 1.3% | 0.5% |
| 1Y | -30.0% | -25.8% | 16.4% |
Return vs Industry: PQ6 underperformed the German Pharmaceuticals industry which returned -25.1% over the past year.
Return vs Market: PQ6 underperformed the German Market which returned 16.6% over the past year.
Price Volatility
| PQ6 volatility | |
|---|---|
| PQ6 Average Weekly Movement | 27.6% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: PQ6's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: PQ6's weekly volatility has increased from 22% to 28% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 40 | Cheryl Maley | starpharma.com |
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications worldwide. The company’s products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It is also involved in the development of dendrimer enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial.
Starpharma Holdings Limited Fundamentals Summary
| PQ6 fundamental statistics | |
|---|---|
| Market cap | €22.13m |
| Earnings (TTM) | -€7.12m |
| Revenue (TTM) | €2.37m |
Is PQ6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PQ6 income statement (TTM) | |
|---|---|
| Revenue | AU$4.16m |
| Cost of Revenue | AU$9.91m |
| Gross Profit | -AU$5.75m |
| Other Expenses | AU$6.78m |
| Earnings | -AU$12.52m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.03 |
| Gross Margin | -138.24% |
| Net Profit Margin | -301.18% |
| Debt/Equity Ratio | 0.5% |
How did PQ6 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/04 18:49 |
| End of Day Share Price | 2025/06/04 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Starpharma Holdings Limited is covered by 12 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dennis Hulme | APP Securities Pty Ltd. |
| Tanushree Jain | Bell Potter |
| Matthijs Smith | Canaccord Genuity |